Core Viewpoint - A securities class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly making false and misleading statements regarding its financial health and operational assumptions during the Class Period from February 5, 2025, to July 23, 2025 [1][2]. Summary by Relevant Sections Allegations Against Molina Healthcare - The lawsuit claims that Molina's management failed to disclose material adverse facts about its medical cost trend assumptions [2] - It is alleged that there was a dislocation between premium rates and medical costs, impacting Molina's near-term growth [2] - The complaint suggests that Molina's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues [2] - Defendants' positive statements regarding the company's business and prospects were deemed materially misleading and lacked a reasonable basis [2] Lead Plaintiff Process - Investors who suffered losses can seek to be appointed as lead plaintiffs by December 2, 2025, through Kessler Topaz Meltzer & Check, LLP or other counsel [3] - The lead plaintiff represents the interests of all class members and selects counsel to direct the litigation [3] - Participation as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4] - The firm emphasizes its commitment to protecting investors and consumers from fraud and negligence [4]

Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims centered around undisclosed adverse financial information and misleading guidance during a specific class period [1][4][5]. Company Overview - Molina Healthcare provides managed healthcare services primarily to low-income families and individuals through Medicaid, Medicare, and state insurance marketplaces [3]. Allegations of the Lawsuit - The lawsuit alleges that Molina Healthcare failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [4]. - It is claimed that Molina's near-term growth relied on reduced utilization of various healthcare services, which was not communicated to investors [4]. - The lawsuit also states that Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced due to these undisclosed factors [4]. Financial Performance and Impact - On July 7, 2025, Molina reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [5]. - Following this announcement, Molina Healthcare's stock price experienced a decline, attributed to the revelation of ongoing medical cost pressures [5]. - On July 23, 2025, Molina further cut its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and projecting adjusted earnings of no less than $19.00 per diluted share for the full year [6]. - This announcement led to a nearly 17% drop in Molina's stock price, reflecting investor reaction to the challenging medical cost environment [6]. Legal Process - Investors who purchased Molina Healthcare securities during the class period have until December 2, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a prominent law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8][9].

Core Insights - Molina Healthcare, Inc. (MOH) is scheduled to report its third-quarter 2025 results on October 22, 2025, with earnings estimated at $3.97 per share and revenues of $10.9 billion [1][7] Earnings Estimates - The earnings estimate for Q3 2025 indicates a year-over-year decrease of 33.9%, while the revenue estimate suggests a growth of 5.4% year over year [2] - For the full year 2025, the revenue estimate is $44.54 billion, reflecting a 9.6% increase year over year, but the earnings per share estimate is $18.87, indicating a decline of 16.7% year over year [3] Historical Performance - Molina Healthcare has beaten the consensus estimate in two of the last four quarters and missed twice, with an average surprise of negative 2.2% [4] Earnings Prediction Model - The current model does not predict an earnings beat for Molina Healthcare, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 (Sell) [5] Membership and Premiums - The Zacks Consensus Estimate for premiums indicates a growth of 6.3% year over year in Q3, with Medicare premiums expected to reach $1.5 billion, up 8% year over year [6][8] - Medicaid membership is projected to decrease by 2.8% year over year, while Medicare membership is expected to grow by 6.5% [8] Medical Care Ratio and Costs - The consensus mark for the medical care ratio (MCR) in the Marketplace is pegged at 84.67%, up from 73% a year ago, and the total MCR is expected to be 90.32%, up from 89.20% [8] - Rising costs and lower investment income are expected to impact earnings, with a projected 15.3% decline in investment income and over 6% increase in total operating expenses [9]

Core Viewpoint - Molina Healthcare, Inc. is facing significant financial challenges, leading to a class action lawsuit for investors who purchased securities during a specified period due to misleading information regarding earnings guidance and medical cost pressures [1][3]. Financial Performance - On July 7, 2025, Molina reported second quarter adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [3]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2% at the midpoint, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [3]. - Molina's stock price fell by $6.97 per share, or 2.9%, closing at $232.61 per share on July 7, 2025, following the earnings announcement [3]. Subsequent Developments - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, now expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [3]. - The company's GAAP net income for the second quarter was reported at $4.75 per diluted share, an 8% decrease year over year [3]. - Molina's stock price experienced a significant drop of $32.03 per share, or 16.84%, closing at $158.22 per share on July 24, 2025, after the second guidance cut [3]. Legal Actions - The Portnoy Law Firm is advising Molina investors about a class action lawsuit for those who bought securities between February 5, 2025, and July 23, 2025, with a deadline to file a lead plaintiff motion by December 2, 2025 [1][2].

LOS ANGELES, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. RCI H ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them before the December 2, 2025 deadline for lead plaintiff applications in a federal securities class action [4][6]. Summary by Sections Company Overview - Molina Healthcare, Inc. is a publicly traded company on the NYSE under the ticker MOH [4]. Allegations and Financial Impact - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and financial guidance for fiscal year 2025 [6]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of various health services, and the likelihood of cutting financial guidance [6]. Financial Results and Stock Performance - On July 7, 2025, Molina announced second-quarter results with adjusted earnings of approximately $5.50 per share, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance to no less than $19.00 per diluted share [8][9]. - This led to a significant stock price drop of $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [9]. Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is December 2, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [10]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct, including whistleblowers and former employees, to contact them [11].

Core Viewpoint - A securities class action lawsuit has been filed against Molina Healthcare, Inc. for allegedly making false and misleading statements regarding its financial health and operational performance during the Class Period from February 5, 2025, to July 23, 2025 [1][2]. Summary by Relevant Sections Allegations Against Defendants - The complaint claims that Molina's management failed to disclose critical adverse facts about the company's medical cost trend assumptions [2] - It is alleged that Molina was facing a dislocation between premium rates and medical cost trends [2] - The company's near-term growth was reportedly reliant on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services [2] - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced [2] - The positive statements made by Molina's management regarding the company's business and prospects were deemed materially misleading and lacking a reasonable basis [2] Lead Plaintiff Process - Investors in Molina have until December 2, 2025, to seek appointment as a lead plaintiff representative for the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4] - The firm aims to protect investors and consumers from fraud and negligence by businesses [4]

Core Insights - The article compiles significant research calls from Wall Street, highlighting upgrades and downgrades of various companies that investors should be aware of [1] Upgrades - BofA upgraded Sea Limited (SE) to Buy from Neutral with a price target of $215, increased from $206, citing strong momentum across its businesses [2] - JPMorgan upgraded Las Vegas Sands (LVS) to Overweight from Neutral with a price target of $60, up from $56, due to a recent pullback in shares and a positive outlook for Singapore [2] - JPMorgan also upgraded PPG (PPG) to Overweight from Neutral, maintaining a price target of $112, believing that PPG's market value has decreased more than its business fundamentals [3] - Seaport Research upgraded TKO Group (TKO) to Buy from Neutral with a price target of $214, becoming more constructive after recent share pullbacks [3] - Wells Fargo upgraded T-Mobile (TMUS) to Overweight from Equal Weight with a price target of $260, up from $250, due to higher expected free cash flow growth and network leadership [4] Downgrades - Bernstein downgraded Lululemon (LULU) to Market Perform from Outperform with a price target of $190, down from $220, citing worsening underlying U.S. trends despite a near-term boost from promotions [5] - TD Cowen downgraded Molina Healthcare (MOH) to Hold from Buy, maintaining a price target of $203, due to potential medical loss ratio pressure from state budget deficits [5] - Deutsche Bank downgraded Fiserv (FI) to Hold from Buy with a price target of $122, down from $175, anticipating a lower 2025 outlook amid deteriorating fundamentals [5] - Rothschild & Co Redburn downgraded Verisk Analytics (VRSK) to Sell from Neutral with a price target of $220, indicating that downside risks are not reflected in the shares [5] - Goldman Sachs downgraded Cricut (CRCT) to Sell from Neutral with a price target of $4.75, down from $5.50, due to limited visibility into sustainable revenue growth beyond 2026 [5]

Core Viewpoint - A lawsuit has been filed against Molina Healthcare, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - Investors have until December 2, 2025, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [2]. - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., et al., No. 25-cv-9461 [2]. Group 2: Company Background - Molina Healthcare is a health insurance company that provides managed healthcare services to low-income individuals under Medicaid and Medicare programs [3]. - The company previously claimed a "solid" earnings growth profile heading into 2025 and stated it was able to mitigate healthcare cost inflation [3]. Group 3: Financial Performance and Stock Impact - On July 7, 2025, Molina reported Q2 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its guidance for expected adjusted earnings per share by 10.2%, revising it to a range of $21.50 to $22.50 per share [4]. - Following further revelations on July 23, 2025, regarding a challenging medical cost trend environment, Molina's stock price fell by $32.03 per share, or 16.8%, from $190.25 to $158.22 [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, due to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Molina Healthcare failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - The lawsuit alleges that Molina's near-term growth relied on a lack of utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be cut, leading to misleading positive statements about the company's business and prospects [5]. Group 2: Participation Information - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must move the Court by December 2, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in 2019 and 2020 [4]. - Investors are encouraged to select qualified counsel with a proven success record, as many firms may lack comparable experience [4].